Skip to main content

Table 2 The prevalence of MAFLD in different subgroups

From: Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population

Variable Category Fraction Prevalence rates (95% CI) p value
Age (years) < 50 145/731 19.8 (17.0–22.9) < 0.001
≥ 50 1426/4646 30.7 (29.4–32.0)  
Sex Male 555/2173 25.5 (23.7–27.4) < 0.001
Female 1016/3204 31.7 (30.1–33.3)  
High school and above No 1259/4407 28.6 (27.2–29.9) 0.030
Yes 309/963 32.1 (29.1–35.1)  
High-income No 638/2460 25.9 (24.2–27.7) < 0.001
Yes 900/2831 31.8 (30.1–33.5)  
Menopause No 83/514 16.1 (13.1–19.6) < 0.001
Yes 932/2689 34.7 (32.9–36.5)  
Hypertension No 457/2241 20.4 (18.7–22.1) < 0.001
Yes 1114/3136 35.5 (33.8–37.2)  
T2DM No 1179/4547 25.9 (24.7–27.2) < 0.001
Yes 392/830 47.2 (43.8–50.7)  
Metabolic dysregulation No 592/3475 17.0 (15.8–18.3) < 0.001
Yes 975/1888 51.6 (49.4–53.9)  
Overweight/obesity No 149/1945 7.7 (6.5–8.9) < 0.001
Yes 1419/3419 41.5 (39.8–43.2)  
Central obesity No 260/2362 11.0 (9.7–12.3) < 0.001
Yes 1307/3001 43.6 (41.8–45.3)  
ALT abnormality No 1406/5063 27.8 (26.5–29.0) < 0.001
Yes 151/264 57.2 (51.0–63.2)  
Hypertriglyceridemia No 690/3463 19.9 (18.6–21.3) < 0.001
Yes 867/1864 46.5 (44.2–48.8)  
HDL-C abnormality No 824/3542 23.3 (21.9–24.7) < 0.001
Yes 733/1785 41.1 (38.8–43.4)  
Hyperuricemia No 738/3349 22.0 (20.6–23.5) < 0.001
Yes 819/1978 41.4 (39.2–43.6)  
High physical activity No 1178/3878 30.4 (28.9–31.9) 0.002
Yes 386/1484 26.0 (23.8–28.3)  
Frequency of soups < 1 per week 584/1772 33.0 (30.8–35.2) < 0.001
≥ 3 per week 474/1475 32.1 (29.8–34.6)  
  1. MAFLD metabolic dysfunction-associated fatty liver disease, T2DM type 2 diabetes mellitus, HDL-C high-density lipoprotein cholesterol, ALT alanine aminotransferase, AST aspartate aminotransferase